New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Nearly two years after FDA issued a final rule requiring radiologists to tell women whether their breasts are “dense” or “not dense” after a mammogram, the notification has become nearly universal.
